Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2445-2451

  Knappe, Daniel ^a   Fritsche, Stefanie ^a   Alber, Gottfried ^a   Köhler, Gabriele ^b   Hoffmann, Ralf ^a   Müller, Uwe ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

AMPs; Antimicrobial peptides; Escherichia coli ATCC 25922; Histopathology; Proline rich peptides; Repeated toxicity; Therapeutic window

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; ONC 72; ONC72; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BEHAVIOR; BLOOD SAMPLING; CONTROLLED STUDY; DEATH; DRUG EFFICACY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EX VIVO STUDY; HISTOPATHOLOGY; LAVAGE; LETHALITY; MOUSE; NONHUMAN; ORGAN; SEPTICEMIA; SURVIVAL RATE; SYSTEMIC SEPTICEMIA; TOXICITY;

ANIMAL STRUCTURES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; INJECTIONS, INTRAPERITONEAL; MICE; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866331981     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks241     Document Type: Article

References (18)

1. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
2. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
3. Andreu D, Rivas L. Animal antimicrobial peptides: an overview. Biopolymers 1998; 47: 415-33.
4. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
5. Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
6. Benincasa M, Pelillo C, Zorzet S et al. The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol 2010; 10: 178.
7. Szabo D, Ostorhazi E, Binas A et al. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Int J Antimicrob Agents 2010; 35: 357-61.
8. Ostorhazi E, Holub MC, Rozgonyi F et al. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int J Antimicrob Agents 2011; 37: 480-4.
9. Ostorhazi E, Rozgonyi F, Sztodola A et al. Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections. J Antimicrob Chemother 2010; 65: 2416-22.
10. Schneider M, Dorn A. Differential infectivity of two Pseudomonas species and the immune response in the milkweed bug, Oncopeltus fasciatus (Insecta: Hemiptera). J Invertebr Pathol 2001; 78: 135-40.
11. Knappe D, Piantavigna S, Hansen A et al. Oncocin (VDKPPYL PRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against Gram-negative human pathogens. J Med Chem 2010; 53: 5240-7.
12. Knappe D, Kabankov N, Hoffmann R. Bactericidal oncocin derivatives with superior serum stabilities. Int J Antimicrob Agents 2011; 37: 166-70.
13. Knappe D, Zahn M, Sauer U et al. Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the high-resolution structure of the oncocin-DnaK complex. Chembiochem 2011; 12: 874-6.
14. Singer D, Zauner T, Genz M et al. Synthesis of pathological and nonpathological human exon 1 huntingtin. J Pept Sci 2010; 16: 358-63.
15. Frimodt-Moller N, Knudsen JD, Espersen F. Handbook of Animal Models of Infection. London: Academic Press, 1999.
16. Langrock T, Garcia-Villar N, Hoffmann R. Analysis of hydroxyproline isomers and hydroxylysine by reversed-phase HPLC and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 282-8.
17. Tavano R, Segat D, Gobbo M et al. The honeybee antimicrobial peptide apidaecin differentially immunomodulates human macrophages, monocytes and dendritic cells. J Innate Immun 2011; 3: 614-22.
18. Czihal P, Knappe D, Fritsche F et al. Api88 is a novel antibacterial designer peptide to treat systemic infections with multi-drug resistant Gram-negative pathogens. Chem Biol 2012; doi: 10.1021/cb300063v.